Connect with us

Asia Pacific & Australia

Former AusCann Exec Layton Mills looks for love in season 10 of Married At First Sight

Published

on


This story via Cannabiz is a perfect illustration of where the Australian Cannabis “industry” (if you want to call it that)  is in 2023.

It’s so attractive that as an exec you’d rather be in a reality show…or, we could look at it another way. The only people the industry can attract are those that would prefer to be in a reality show.

There is a paucity of imagination in this little parable that explains why the Austrlian cannabis sector in it’s present form is not going anywhere.

Not to put too fine a line on it but reading below it’s hard not to retch at the repulsiveness of it all

 

AusCann chief executive Layton Mills has vowed to put love before loot by joining the cast for Season 10 of reality TV show Married At First Sight (MAFS).

Mills quit AusCann in September 2022 after 18 months at the helm, pledging to continue to support the company during a six-month notice period before “pursuing other business interests”.

Mills took over as AusCann CEO from Nick Woolf in January 2021 following AusCann’s acquisition of CannPal Animal Therapeutics, a business Mills founded.

Now his next move has been revealed, with Channel 9 describing the 35-year-old New South Welshman as “an entrepreneur [who] has started a number of successful businesses, including his latest project in medicinal cannabis for pets”.

However, his success in business appears to have come at the expense of his love life, according to the program’s makers.

“While describing himself as motivated and driven in his businesses, Layton is less committed to making love a priority,” says the MAFS website.

“He struggles to compromise, so more often than not he puts work first. This sees him spending more time in the office, on his computer and in meetings than with a significant other, which takes its toll on relationships.”

Luckily, Mills seems prepared to make changes to his work-life balance for the greater good.

Read more at CANNABIZ

 

 



Source link

Continue Reading

Asia Pacific & Australia

Paper – Australia: NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development.

Published

on

By


An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022. The service provided comprehensive patient-specific and evidence-based information to support health professionals in prescribing and patient care decisions. This study aimed to describe real-world data collected by CMAS.

A sub-set of de-identified, patient-specific enquiries collected between January 2021 and June 2022 (n = 123/567; 21.7%) were analyzed using R version 4.2.1. Diagnosis, indication, and comorbidities were coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology.

Most patient-specific enquiries from medical practitioners were from general practitioners (n = 103/123; 83.7%). Female (n = 53/123; 43.1%) and male (n = 59/123; 48.0%) patients were similarly represented. Sex was not specified for 8.9% (n = 11/123) of patients. The mean age of patients was 52.1 years (range <10-90). The most common three diagnoses were osteoarthritis, anxiety, and chronic pain. Indications that were most frequently reported included chronic pain, anxiety, back pain, non-neuropathic pain, and insomnia. Comedications were most commonly non-opioid and opioid analgesics and antidepressants. Most practitioners were considering prescribing a cannabidiol (CBD) product for their patient. Cannabinoid composition selection guidance provided by CMAS was predominantly (delta-9-tetrahydrocannabinol) THC:CBD ~1:1, followed by CBD-only products. CMAS was contacted by health professionals regarding the management of potential adverse events for five patients.

The findings of this study shed light on the information medical practitioners were seeking to inform their clinical decision-making about medical cannabis and can inform the development of clinical guidance resources.

© 2024 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.



Source link

Continue Reading

Asia Pacific & Australia

Australia’s Zenith Cannabis Clinic Throws Up More Question Marks.. It Appears They Are Providing Consults But Have No TGA Approval To Prescribe

Published

on

By


Hi I noticed you had a post about Zenith clinics I recently had a run in with them as I was seeking medication.

They are a scam they take your money which was $29 for the initial consult which they say they will return it’s just a pending holding fee for the consult.

A “so called doctor gives you a call on zoom they prescribe you”.

After two weeks nothing happened I called several times and got the same person with a south African accent they keep on telling me they are waiting for TGA approval this goes on and on they say it sometimes takes a long time.

I was fed up so I called ******* scripts got a free appointment the next day she prescribed me and the TGA approval only took 48hrs and I have the product now already.

I am yet to hear back from Zenith clinic. It’s not the money as it was only $29 but it’s the deception they must be doing this to a lot of people who really need medicine. I wanted to send this as people need to be warned so they are to right decision.



Source link

Continue Reading

Asia Pacific & Australia

SOMAI Boss Says Australian Medical Cannabis Programme Is World Beater

Published

on

By


Respectfully we’d disagree – this is what he told Cannabiz Australia

 

The Australian medical cannabis industry may have its challenges, but its focus on affordable access and patient care make it a role model for the rest of the world, says SOMAÍ Pharmaceuticals chairman and CEO Michael Sassano. 

The Australian market has become one of only three significant global medical cannabis markets in the world.

Although all eyes are on the US potentially rescheduling the substance after Germany removed the narcotics label from cannabis medicines, the Australian market continues to expand faster than most because of the focus on what is best for patients and their experience.

Australia leads in cannabis choice and pricing

Doctor and patient relationships and freedom of choice for both parties help to form the foundation of a solid medical cannabis market. When the focus is on limiting access instead, problems arise.

Michael Sassano

For example, Israel only permits flower sales and limits other products, such as extracts. Germany’s market focuses on the magistral preparation of extracts with a minimal framework for different form factors like gel capsules or faster-acting excipients.

As another example, seniors in the US are a growing market that may consume cannabis in low dosages for arthritis. Their preferred administrative and dosage choice is a mild 1:50 gel capsule or edible format. With flower-only restrictions, they would have to roll a joint or use a smoking pipe instead. Massive market segments are being excluded from access because they simply don’t want to smoke.

Australia is far beyond other larger markets regarding choice with patients having close to 1,000 medical cannabis product choices. Giving options to doctors and patients is precisely what the cannabis-as-medicine movement has always been about, not a one-size-fits-all therapy program.

The country has also embraced lower consumer pricing, making daily medicine more affordable and accessible. All favourable consumer markets give patients ample choice and affordable pricing, providing access to everyday necessities.

Read the full article

When it comes to access, the rest of the world should follow Australia’s example

 



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media